Sernova Biotherapeutics Inc
SEOVF
$0.1422
$0.01249.55%
OTC PK
| 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -24.60% | -8.48% | 12.49% | -24.98% | 63.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -54.52% | -60.57% | -32.16% | -0.28% | 16.30% |
| Operating Income | 54.52% | 60.57% | 32.16% | 0.28% | -16.30% |
| Income Before Tax | 44.53% | 57.84% | 26.06% | -6.19% | -21.36% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 44.47% | 57.78% | 26.06% | -6.19% | -21.36% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 44.47% | 57.78% | 26.06% | -6.19% | -21.36% |
| EBIT | 54.52% | 60.57% | 32.16% | 0.28% | -16.30% |
| EBITDA | 54.50% | 61.48% | 32.68% | -0.46% | -16.54% |
| EPS Basic | 48.74% | 59.51% | 26.12% | -6.61% | -21.43% |
| Normalized Basic EPS | 48.99% | 59.55% | 26.14% | -6.34% | -21.14% |
| EPS Diluted | 48.74% | 59.51% | 26.12% | -6.61% | -21.43% |
| Normalized Diluted EPS | 48.99% | 59.55% | 26.14% | -6.34% | -21.14% |
| Average Basic Shares Outstanding | 7.96% | 4.67% | 0.09% | 0.02% | 0.00% |
| Average Diluted Shares Outstanding | 7.96% | 4.67% | 0.09% | 0.02% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |